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Background/Aims
Proton pump inhibitors (PPIs) which are the most effective agents for the treatment of gastroesophageal reflux disease (GERD), 
have been known to delay gastric emptying. Mosapride has been used as prokinetics by accelerating gastric emptying. We 
evaluated the efficacy of mosapride to prevent PPI-induced delayed gastric emptying in a prospective randomized, double-blind 
and placebo-controlled trial.
Methods
Thirty patients who were diagnosed as GERD and had normal gastric emptying were included in this study. PPI monotherapy 
group was treated with placebo drug in addition to pantoprazole and PPI plus mosapride group was treated with mosapride in  
addition to pantoprazole for 8 weeks. Gastric emptying scan and questionnaires about GERD and dyspeptic symptoms were as-
sessed by scoring before and after treatment. To evaluate the changes of gastrointestinal endocrine hormones by PPI which are 
associated gastric acid secretion and gastric motility, fasting plasma gastrin and cholecystokinin were taken at weeks 0 and 8.
Results
Half gastric emptying time was increased (P = 0.023) in PPI monotherapy group, and there were no significant changes in  
PPI plus mosapride group. Plasma gastrin level increased in PPI monotherpay group (P = 0.028) and there were no significant 
changes in PPI plus mosapride group. Plasma cholecystokinin level was not changed after treatment in both groups. GERD 
symptoms were improved after treatment in both groups, and postprandial bloating and nausea were improved in PPI plus 
mosapride group. 
Conclusions
Mosapride showed to be effective in preventing delayed gastric emptying and the increase in plasma gastrin level induced by 
PPI treatment, but did not show prominent clinical symptom improvements.
(J Neurogastroenterol Motil 2013;19:495-502)
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Figure 1. Study flow diagram. CCK, 
cholecystokinin.
Introduction
Gastroesophageal reflux disease (GERD) is one of the most 
common disease characterized by reflux symptoms like heartburn 
and acid regurgitation.1,2 The treatment of GERD is based on 
anti-secretory compounds, including histamine H2-receptor an-
tagonists (H2RAs) and proton pump inhibitors (PPIs).
3 PPIs 
are widely used due to providing more long-lasting symptom re-
lief with esophageal healing than any other available drugs in-
cluding H2RAs, currently.
4
However, PPIs have been known to delay gastric emptying 
from 15% to 40%.5-7 The mechanisms for delayed gastric empty-
ing induced by PPIs were discussed as decreased gastric acid 
which resulted in inadequate hydrolysis of food, enhanced secre-
tion of gastrin, and decreased fluid secretion into the stomach.6,8,9 
Delayed gastric emptying could influence functional gastro-
intestinal disorders including gastroesophageal reflux disease, 
peptic ulcer disease and functional dyspepsia.10-12
Mosapride is a selective 5-hydroxytryptamine type 4 (5- 
HT4) receptor agonist and has been used in patients with upper 
gastrointestinal disorders by shortening gastric emptying in 
healthy volunteers and gastroparesis.13,14
Gastrin and cholecystokinin (CCK) are homologous gastro-
intestinal endocrine hormones which are known to regulate gas-
tric acid secretion, gastric emptying, growth of gastric mucosa 
and intestinal motility in upper gastrointestinal tract.15-17
We conducted a prospective randomized, double blind and 
placebo-controlled clinical trial to evaluate the hypothesis that 
mosapride can normalize or prevent PPI-induced delayed gastric 
emptying, and we evaluated the changes of gastrointestinal endo-
crine hormones and upper gastrointestinal symptoms between 
PPI monotherapy group and PPI plus mosapride group.
Materials and Methods
Setting and Participants
Patients were recruited from the Gangnam Severance 
Hospital, Yonsei University, Korea, between September 2008 
and June 2010. The study was conducted in accordance with the 
Declaration of Helsinki and this study protocol was approved by 
the Yonsei University College of Medicine Ethics Committee. 
Written informed consents were obtained from all patients prior 
to participation. The patients who were diagnosed as GERD by 
applying the Montreal criteria and had normal gastric emptying 
were included.18 Exclusion criteria included patients (1) who had 
organic gastrointestinal disease including inflammatory bowel 
disease, cancer and ulcer (2) who took drugs which could affect 
evaluation of the treatment; other PPIs, H2RAs, prokinetics, 
mucosal protective agents, antacids, cholinergic and anti-
cholinergic agents, and antidepressants for at least 4 weeks prior 
to study start, (3) who had severe systemic diseases including 
hepatic and nephrotic disease, (4) who had previous gastrectomy 
history, and (5) who was in state of pregnancy.
Study Design and Treatment Protocol
Medication protocol
Patients in PPI monotherapy group were given pantoprazole 
40 mg once daily (ⓇPantoloc; Pacific Pharma Co. Ltd., Seoul, 
Korea) and placebo tablets that were identical to mosapride cit-
rate tablets t.i.d (3 times a day) (Daewoong Pharm Co. Ltd., 
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Seoul, Korea) for 8 weeks. Patients in PPI plus mosapride group 
were given pantoprazole 40 mg once daily and mosapride citrate 
(ⓇGasmotin; Daewoong Pharma Co. Ltd., Seoul, Korea), 5 mg 
t.i.d for 8 weeks. The drugs which could affect the gastro-
intestinal function and gastric acid secretion were not allowed to 
be used throughout the study.
Visit Schedule and Outcome Assessments 
(Fig. 1)
This study was conducted as a prospective randomized, dou-
ble-blind, placebo-controlled study. After informed consent was 
obtained, the screening examinations were conducted including a 
complete medical history, esophagogastroduodenoscopy, and 
blood sampling. Patients recorded questionnaires regarding gas-
troesophageal reflux symptoms including heartburn, acid regur-
gitation and dyspeptic symptoms including nausea/vomiting, 
belching, postprandial fullness, postprandial bloating and early 
satiety. The symptom severity was assessed with response options 
as no symptom (0), mild (1), moderate (2) or severe (3). Patients 
who were determined to meet all inclusion/exclusion criteria were 
randomized into 2 study group by PPI monotherapy group and 
PPI plus mosapride group, and underwent the first gastric emp-
tying study and serum test for fasting plasma gastrin and plasma 
CCK. 
After 8 weeks of drug treatment, all subjects visited hospital 
for a second gastric emptying study. Symptom scores were 
checked by questionnaires about gastroesophageal reflux symp-
toms, dyspeptic symptoms and any reported adverse events were 
checked in this visit. The patients who consented blood sam-
plings were checked on the plasma gastrin and plasma CCK.
Quantification of Gastric Emptying
Gastric emptying scan was assessed by a standardized scin-
tigraphy method.19,20 After a 12 hour fast, patients underwent 
scintigraphy after ingestion of the standard solid meal in the sit-
ting position. The solid meal was consisted of 50 g of scrambled 
eggs (75 kcal) and 210 g of boiled rice (315 kcal, Korean stand-
ard diet) which was labeled with 500 μCi of 99 mTc-pertechnate. 
The contents of the radioactive materials in the stomach were 
measured by external scintigraphy using a gamma camera with a 
low-energy, all-purpose, parallel-hole collimator, immediately 
following completion of meal and then at 30, 60 and 90 minutes 
after the end of meal. The main parameters were half gastric 
emptying time (T1/2, minutes) and percentage of gastric retention 
at 30, 60 and 90 minutes. T1/2 was defined as the time taken to 
empty 50% of the gastric content. 
Plasma Gastrin and Cholecystokinin
Whole blood samples (5 mL) were collected from patients af-
ter fasting for 12 hours. Blood samples were immediately centri-
fuged and then stored at -20oC until the assay. Plasma gastrin-17 
level was determined by using enzyme immunoassays kit (Biohit 
Plc., Helsinki, Finland) and plasma CCK level was measured 
with enzyme immunoassays kit (Phoenix Pharmaceuticals, CA, 
USA) with range of 0-100 ng/mL. 
Statistical Methods
Demographic characteristics and individual symptom scores 
from baseline and follow-up visit were compared between PPI 
monotherapy group and PPI plus mosapride group by the stu-
dent’s t test, or by the nonparametric Mann-Whitney U test if 
required. In addition, T1/2 and residual gastric contents at 30, 60 
and 90 minutes calculated by gastric emptying scan and fasting 
plasma gastrin (pg/mL) and CCK (ng/mL) level from baseline 
and follow-up visit were compared between PPI monotherapy 
group and PPI plus mosapride group by the student’s t test. Data 
are presented as mean ± standard error and all efficacy analyses 
were based on two-sided tests, with P ≤ 0.05 considered as sig-
nificant. All analyses were performed using SPSS 12.0 (SPSS 
Inc., Cary, NC, USA).
Results
Participant Flow and Follow-up
Thirty-eight patients screened (mean age 50.8 years [range 
20-70]; 19 males, 19 females) were randomized into the study ei-
ther as PPI monotherapy group or PPI plus mosapride group in 
accordance with the study design (Fig. 2). Eight patients dis-
continued the study, and there were no statistical differences in 
demographic characteristics between both groups (Table).
Gastric Emptying Scan
Results of gastric emptying between pre-treatment vs post- 
treatment are presented in Figure 3. PPI monotherpy sig-
nificantly delayed gastric emptying increasing T1/2 from 57.5 ± 
12.9 minutes to 88.5 ± 48.2 minutes (P = 0.023). The con-
comitant use of PPI and mosapride, showed no significant 
changes in gastric emptying; T1/2 from 61.2 ± 17.8 minutes to 
65.0 ± 15.5 minutes (P = 0.536).
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Figure 2. Flowchart of patient manage-
ment in the study. CCK, cholecystokinin.
Table. Demographic Characteristics by Treatment Group
PPI group (n = 15) PPI + mosapride group (n = 15) P-value
Age (mean age [range], yr) 53.27 (25-66) 48.47 (20-70) 0.302
Sex (M:F) 10:5 6:9 0.153
Height (mean ± SE) 166.7 ± 6.5 163.7 ± 9.7 0.328
Weight (mean ± SE)     65.9 ± 10.2     62.2 ± 12.9 0.404
PPI, proton pump inhibitor.
Figure 3. Effect of proton pump inhibitor (PPI) plus placebo drugs (n
= 15) and PPI plus mosapride (n = 15) for 8 weeks on time to gastric
half-emptying (T1/2) (mean ± SEM). *P ＜ 0.05.
When examined sequentially over time, PPI increased gas-
tric retention (i.e., delayed gastric emptying) by 12.1 ± 7.9% (P 
= 0.006) at 30 minutes, 17.9 ± 7.6% (P = 0.005) at 60 minutes, 
and 19.5 ± 8.0% (P = 0.006) at 90 minutes when compared 
with baseline (Fig. 4A). In contrast, in the group receiving PPI 
plus mosapride, gastric retention was not changed at 30, 60 and 
90 minutes compared with baseline (Fig. 4B).
Fasting Plasma Gastrin and Cholecystokinin
Plasma gastrin levels were within normal range (＜ 50 
pg/mL) in both groups at baseline, but showed significantly 
higher level in PPI monotherapy group after treatment end 
points (46.58 pg/mL vs. 103.11 pg/mL, P = 0.028) (Fig. 5A). 
Plasma CCK was within normal range in baseline and there were 
no significant changes after treatment in both groups (Fig. 5B).
Clinical Efficacy Parameters
Gastoesophageal reflux symptoms were improved after treat-
ment and there were no significant differences between 2 groups 
(Fig. 6). In the aspect of dyspeptic symptom, belching and post-
prandial fullness were improved in PPI monotherapy group. 
Nausea/vomiting and postprandial bloating additional to belch-
ing and postprandial fullness were improved in PPI plus mo-
Effects of Mosapride to PPI in GERD
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Figure 4. (A) Effect of proton pump inhibitor (PPI) plus placebo drugs (n = 15) for 8 weeks on percentage of gastric retention at 30, 60 and 90 
minutes after test meal (mean ± SEM) and (B) PPI plus mosapride (n = 15) for 8 weeks on percentage of gastric retention at 30, 60 and 90 minutes 
after test meal (mean ± SEM.). *P ＜ 0.05.
Figure 5. (A) Changes in fasting plasma gastrin level between proton pump inhibitor (PPI) + placebo group (n = 11) and PPI + mosapride group 
(n = 11) before and after treatment (B) Changes in fasting cholecystokinin gastrin level between PPI + placebo group (n = 11) and PPI + mosapride
group (n = 11) before and after treatment. *P ＜ 0.05.
sapride group. Early satiety did not show significant change after 
treatment in both groups (Fig. 7).
Adverse Events
Neither group of volunteers reported any severe side effects 
or clinically significant adverse events after randomization and 
during drug treatment. All adverse events were mild. In PPI 
monotherapy group, abdominal bloating (1 occurrence) and 
vomiting (1 occurrence) were noted, and in PPI plus mosapride 
group, vomiting (2 occurrences) and abdominal pain (1 occur-
rence) were reported.
Discussion
The main treatment for GERD is potent acid suppression by 
using PPI.21,22 Adding prokinetic drugs to PPI in the treatment 
of GERD is recommended, due to enhancing esophageal motor 
function, although the efficacy is controversial.23-27 PPI induced 
the delay of gastric emptying in solid food, but there was few liter-
ature about prevention of the treatment delayed gastric emptying, 
and evaluations on dyspeptic symptoms.8,28-30 Tegaserod (5-HT4 
receptor agonist) was used to normalize the delayed gastric emp-
ting caused by PPIs in previous study, but tegaserod is out of 
market from its cardiovascular risk, so there is no proven safe 
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Figure 6. Changes in gastroesophageal reflux symptoms (acid 
regurgitation and heartburn) between the proton pump inhibitor (PPI) 
+ placebo group (n = 15) and the PPI + mosapride group (n = 15) 
before and after treatment. *P ＜ 0.05.
Figure 7. Changes in dyspeptic sym-
ptoms (nausea/vomiting, belching, post-
prandial fullness, postprandial bloating 
and early satiety) between the proton 
pump inhibitor (PPI) + placebo group 
(n = 15) and the PPI + mosapride 
group (n = 15). *P ＜ 0.05.
drug which was studied for preventing the PPI induce delayed 
gastric emptying.
In present study, the efficacy of mosapride citrate for pre-
venting the PPI induced gastric emptying was assessed. Mos-
apride citrate, a 5-HT4 receptor agonist, is a prokinetic drug used 
in functional gastrointestinal disorder including gastroesophageal 
reflux disease and functional dyspepsia and is safe for it does not 
cause QT prolongation.31,32 The action mechanism of mosapride 
includes enhancement of esophageal motor function, acceleration 
of gastric emptying, and enhanced acid inhibitory effect of PPIs 
in humans.23,33-35
In this study, PPI treatment was associated with significant 
delays in gastric emptying by 53.9% prolongation in T1/2 com-
pared to baseline which was slightly higher than the previous re-
port with 15-40% delay in T1/2 during PPI treatment.
5,36 
However, with mosapride added to PPI, the delayed gastric 
emptying did not occurr. The delaying effect of PPI on gastric 
emptying appears to be manifested by the increase in percentage 
of meal retained at 30, 60 and 90 minutes compared with 
pre-treatment baseline values. The observation in this study is 
that mosapride effectively prevented the delay in gastric emptying 
induced by PPI as by the prokinetic effect.
In aspect of gastrointestinal endocrine hormones, plasma 
gastrin level was increased in PPI monotherapy group as is 
known,15 but there was no significant change in PPI plus mo-
sapride group after treatment. The mechanism for the normal-
ization of gastrin level in PPI plus mosapride group could be as 
follows: emptying of solid food contents in the stomach increases 
by mosapride and less acid secretion for hydrolysis is needed 
compared to PPI monotherapy. Lowered needs for the acid se-
cretion could inhibit the increase in the plasma gastrin level and 
consequently G-cell hyperplasia by the feedback mechanism. 
Although more study in gut hormone changes by prokinetic drug 
is needed, PPI plus mosapride therapy could prevent the dyspep-
tic symptom development after discontinuation of PPI by inhibit-
ing increased serum gastrin level and G cell hyperplasia.
CCK is known to be associated with decrease of antral mo-
tility and previous studies showed that PPI induced the decrease 
Effects of Mosapride to PPI in GERD
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of plasma CCK, but in our study there was no significant change 
in plasma CCK level after treatment.37,38 In addition to the fasting 
state in this study, complementary measurements of the post- 
prandial CCK level would be needed to clarify the relationship 
between gastrointestinal symptom and plasma CCK level.
In the aspect of association of the endocrine hormone changes 
and delayed gastric emptying after PPI therapy, plasma gastrin is 
more related to regulation of gastrointestinal motility rather than 
plasma CCK.
In symptomatic aspects, reflux symptoms including heart-
burn and acid regurgitation were improved both in PPI mono-
therpy and PPI plus mosapride group, and there were no sig-
nificant difference between both groups, as reported in previous 
studies.32 In dyspeptic symptoms, belching and postprandial full-
ness were improved in both group, but nausea and postprandial 
bloating symptoms were improved in PPI plus mosapride group. 
This could be an evidence that mosapride improved dyspeptic 
symptoms by additional gastroprokintic effect, but this study had 
a limitation because baseline symptom scores before treatment in 
PPI plus mosapride group was higher than PPI monotherapy. 
The early satiety symptom was not improved in both groups, and 
it could be partially explained by the unchanged CCK level which 
shows the control of food intake.39 Reason for the mismatching of 
gastric emptying and dyspeptic symptoms is that functional dys-
pepsia is multifactorial pathogenesis, which includes delayed gas-
tric emptying, impaired gastric accommodation of food intake, 
and hypersensitivity to gastric distention.
In summary, we found that mosapride combination therapy 
to PPIs prevent PPI-induced delayed gastric emptying and in-
creased plasma gastrin level, and there were mild improvements 
of dyspeptic symptoms. There are several limitations in our study, 
resulting from factors such as the small number and the charac-
teristics of subjects (i.e., sex difference) due to dropped-out. 
Although larger-scale trial is needed to validate the clear benefit 
of mosapride in the clinical symptom improvements by prevent-
ing delayed gastric motility when using PPIs, data in this study 
provide evidence that PPIs plus mosapride combination therapy 
in GERD is able to prevent dyspeptic symptoms induced by the 
long-term maintenance treatment or after the discontinuation of 
PPIs therapy.
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